Stemline Therapeutics (Stemline Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Mar. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Stemline Therapeutics Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Stemline Therapeutics's net issuance of preferred for the three months ended in Mar. 2020 was $0.00 Mil. The number is 0, which means that Stemline Therapeutics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Stemline Therapeutics's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2020 was $0.00 Mil.

Stemline Therapeutics Net Issuance of Preferred Stock Historical Data

The historical data trend for Stemline Therapeutics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stemline Therapeutics Net Issuance of Preferred Stock Chart

Stemline Therapeutics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Stemline Therapeutics Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Stemline Therapeutics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Stemline Therapeutics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Stemline Therapeutics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Stemline Therapeutics (Stemline Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stemline Therapeutics Inc (NAS:STML) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

750 Lexington Avenue, 11th Floor, New York, NY, USA, 10022

Website

http://www.stemline.com

Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. Its pipeline product candidates include felezonexor (SL-801, an XPO1 inhibitor), SL-1001 (a RET kinase inhibitor), SL-901 (a kinase inhibitor) and SL-701 (an immunotherapy). The company is also involved in advancing its clinical stage programs, expanding and strengthening its intellectual property portfolio, identifying and acquiring additional product and technology rights.

Executives

Darren S Cline	director	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Kenneth J Zuerblis	director	20 KINGSBRIDGE RD, PISCATAWAY NJ 08854
Daniel Hume	director	3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Kenneth Hoberman	officer: Chief Operating Officer	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Ron Bentsur	director	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Alan S Forman	director	55 WHITNEY AVENUE, 5TH FLOOR, NEW HAVEN CT 06511
Eric Dobmeier	director	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
J Kevin Buchi	director	41 MOORES ROAD, FRAZER PA 19355
Eric K Rowinsky	officer: Chief Medical Officer	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014